DY
LCTX icon

Dowling & Yahnke’s Lineage Cell Therapeutics LCTX Stock Holding History

Dowling & Yahnke’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$36K Hold
32,263
– – ﹤0.01% 371
2022
Q2 		$51K Buy
+32,263
New +$42.5K ﹤0.01% 370

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return

Dowling & Yahnke's LCTX Position: Q3 2022 in Review

Dowling & Yahnke held its Lineage Cell Therapeutics (LCTX) position steady in Q3 2022 at 32,263 shares worth $36K. The position accounts for ﹤0.01% of the portfolio, ranked #371.

Dowling & Yahnke first reported a position in LCTX in Q2 2022 and has held it in 2 quarters since. The position peaked at $51K in Q2 2022. 105 funds tracked by Wall St. Rank hold LCTX as of Q3 2022.

  • Dowling & Yahnke held 32,263 shares of Lineage Cell Therapeutics worth $36K as of Q3 2022.
  • Dowling & Yahnke left its Lineage Cell Therapeutics share count unchanged in Q3 2022.
  • Lineage Cell Therapeutics made up ﹤0.01% of Dowling & Yahnke's portfolio in Q3 2022, its #371 holding.
  • Dowling & Yahnke first reported a position in Lineage Cell Therapeutics in Q2 2022 and has held it in 2 quarters since.
  • Dowling & Yahnke's Lineage Cell Therapeutics position peaked at $51K in Q2 2022.
  • 105 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2022.

Based on Dowling & Yahnke's 13F filing for Q3 2022, filed 3 Nov 2022.